TransThera Sciences presents tinengotinib preclinical data at AACR annual meeting

• TransThera Sciences will present a poster at AACR Annual Meeting on April 20, 2026, 9:00 AM–12:00 PM PDT.
• Presentation will cover endocrine therapy resistance in HR+ breast cancer, citing convergent FGFR-JAK signaling as a driver of lineage reprogramming.
• Poster will also show preclinical data indicating tinengotinib restored luminal identity, resensitizing resistant models to endocrine therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences (Nanjing) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260421-12113014), on April 21, 2026, and is solely responsible for the information contained therein.